Financial Performance
FY26 was a landmark year for Emcure as it surpassed the $1 billion revenue mark, totaling ₹9,204 crore. This performance was underpinned by a 22.2% revenue jump in international markets, where Europe and Canada showed robust traction. The company reported an adjusted PAT growth exceeding 40% for the full year.
EBITDA margins improved significantly to 19.4%, reflecting a better product mix and operating leverage. However, the domestic business faced headwinds in the fourth quarter, growing only 5.2% due to restructuring-led attrition in the Zuventus portfolio, although the core domestic segments like Women's Health and Cardiac remained resilient.
Management Outlook
Management has guided for low-to-mid teens revenue growth for FY27, backed by a strong pipeline of specialty launches. A primary objective is the expansion of EBITDA margins by 75 to 100 basis points, assuming stable macroeconomic and regulatory conditions. The company is focusing on high-entry-barrier products, including antibody-drug conjugates (ADCs) and complex injectables.
In the domestic market, management indicated that the Zuventus restructuring is largely complete, with field force productivity and volumes expected to recover starting from the first quarter of FY27. R&D investments remained steady at approximately 4.2% of total revenue.
Key Strategic Developments
- Exclusive India partnership for Povistha (Semaglutide) showing promising early uptake post-April 2026 price adjustments
- Received CDSCO Subject Expert Committee endorsement for Bevacizumab; H1 FY27 launch planned
- Expansion of the oncology and nephrology portfolios through new distribution agreements with Roche and Sanofi
- Acquisition of the Mans portfolio in the UK and Cutivate in Canada to strengthen international dermatology and chronic presence
- Ongoing debt management following the minority stake buyout in Zuventus to achieve full consolidation benefits
Operational Milestone
FY26 marks the start of our five-year strategy focusing on turning last year's operational changes into measurable outcomes. I am very happy to tell my investors that we crossed a major milestone this year, surpassing $1 billion in revenue.
What to Watch
- Commercialization timeline and market penetration of the Bevacizumab biosimilar in H1 FY27
- Recovery of field force productivity in the Zuventus portfolio following the Q4 restructuring
- Impact of volatile raw material costs on gross margins despite current inventory cushions
- Progress of the Antibody-Drug Conjugate (ADC) program towards clinical milestones
